Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial

Manpreet K. Singh, MD, MS,1 Andrei Pikalov, MD, PhD,2 Cynthia Siu, PhD,3 Michael Tocco, PhD,2 and Antony Loebel, MD2

Abstract

Objectives: To evaluate the efficacy and safety of lurasidone in the treatment of children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features.

Methods: Patients, 10–17 years of age, with a Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5), diagnosis of bipolar I depression were randomized to 6 weeks of double-blind treatment with once-daily flexible doses of lurasidone 20–80 mg or placebo. The presence of mixed (subsyndromal hypomanic) features in this pediatric bipolar depression trial was defined as a Young Mania Rating Scale score of 5 or greater at study baseline. Key efficacy measures included change from baseline to week 6 in the Children’s Depression Rating Scale-Revised (CDRS-R) score (primary endpoint) and Clinical Global Impressions-Bipolar Severity (CGI-BP-S) score, using a mixed model for repeated measures analysis.

Results: At baseline, subsyndromal hypomanic features were present in 54.2% of patients. Treatment with lurasidone (vs. placebo) was associated with significantly greater reductions in CDRS-R scores at week 6, independent of the presence (−21.5 vs. −15.9, p < 0.01; effect size d = 0.43) or absence (−20.5 vs. −14.9, p < 0.01; d = 0.44) of subsyndromal hypomanic features. Likewise, lurasidone (vs. placebo) was associated with significantly greater reductions in CGI-BP-S scores at week 6, independent of the presence (−1.6 vs. −1.1, p < 0.001, d = 0.51) or absence (−1.3 vs. −1.0, p = 0.05; d = 0.31) of these subsyndromal hypomanic features. Rates of protocol-defined treatment-emergent hypomania or mania were similar for lurasidone and placebo in patients with (lurasidone 8.2% vs. placebo 9.0%) or without subsyndromal hypomanic features (lurasidone 1.3% vs. placebo 3.7%).

Conclusions: In this post hoc analysis of a randomized placebo-controlled trial, lurasidone was found to be efficacious in the treatment of child and adolescent patients with bipolar depression who presented with mixed (subsyndromal hypomanic) features. No differences in safety profile, including the risk of treatment-emergent mania, were observed in patients with or without subsyndromal hypomanic features in this study.

Keywords: bipolar depression, mixed (subsyndromal hypomanic) features, children and adolescents, lurasidone

Introduction

Pediatric bipolar disorder is a disabling condition associated with long-term psychiatric comorbidity and physical health problems (Findling et al. 2001; Youngstrom et al. 2005; Axelson et al. 2006) that increase the risk of suicide attempt (Goldstein et al. 2005; Algorta et al. 2011), substance abuse, and impaired functioning (Goldstein et al. 2009; Keenan-Miller and Miklowitz 2011). The prevalence of bipolar disorder in children and adolescents ranges from 1% to 3% (Chang 2007; Merikangas et al. 2007; Van Meter et al. 2011; Birmaher 2013) and may be higher if subsyndromal spectrum conditions are included (Dilsaver et al. 2005;...
LURASIDONE FOR MIXED FEATURES IN YOUTH

Objective of this study was to evaluate the efficacy and safety of lurasidone in children and adolescents with mixed (subsyndromal hypomanic) features during episodes of bipolar depression.

Methods

Patients and study design

This post hoc analysis was based on a previously reported placebo-controlled, lurasidone monotherapeutic study in children and adolescents with bipolar depression (ClinicalTrials.gov identifier: NCT02046369) (Delbello et al. 2017). This multicenter study was conducted from March 2014 to October 2016 over 30 months of recruitment at 64 clinical sites in 11 countries. The study was approved by the institutional review board at each investigational site and conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and with the ethical principles of the Declaration of Helsinki. Informed assent and consent were obtained from all patients and their legal guardians, respectively, at study entry and before commencement of any study procedures. Pediatric patients 10–17 years of age, inclusive, with a DSM-5 diagnosis of bipolar I depression, with or without rapid cycling disease course, and without psychotic features, were randomized to 6 weeks of double-blind treatment with a once-daily flexible dose of lurasidone, 20–80 mg, or placebo (Delbello et al. 2017). Eligible patients were required to have a Young Mania Rating Scale (YMRS) score of ≤15, with a YMRS item 1 (elevated mood) score ≤2 at screening and baseline. Subjects randomized to lurasidone were started on 20 mg/day during week 1 and then permitted to dose flexibly from 20 to 80 mg/day.

The eligibility screening procedure in this study required confirmation of the bipolar I disorder diagnosis verified by a trained clinician at the time of screening and by means of the Schedule for Affective Disorders and Schizophrenia for School-age Children (K-SADS-PL) structured clinical interview. The current episode of major depression associated with bipolar I disorder was confirmed and documented by the investigator. In an effort to improve the consistency of subject assessment and rater precision across sites, an independent rater qualification service, Bracket, in collaboration with the sponsor, developed a credential and experience survey to identify raters with appropriate experience and developed an educational program to train these raters for reliability. The training provided consistent rater training and standardization for the Children’s Depression Rating Scale-Revised (CDRS-R), Clinical Global Impressions-Bipolar Severity of Depression Score (CGI-BP-S), YMRS, Pediatric Anxiety Rating Scale (PARS), Children’s Global Assessment Scale (CGAS), and the other rating scales used in this study. In addition, raters were qualified on the CDRS-R assessment. All diagnoses and symptom assessments were conducted by qualified raters with demonstrated inter-rater reliability (DelBello et al. 2017).

Definition of subsyndromal hypomania features

Based on a median split of the study sample, a YMRS (Young et al. 1978) score ≥5 was used to define the presence of mixed (i.e., subsyndromal hypomanic) features at study baseline. We also conducted a sensitivity analysis using an alternative definition of subsyndromal hypomanic features that required the presence of two or more YMRS symptoms, each with a severity score of ≥2 at study baseline (Goldberg et al. 2009; Zimmermann et al. 2009; Azorin et al. 2012; Swann et al. 2013; Tohen et al. 2014).

Assessments

The primary endpoint in the underlying study was the change in the CDRS-R (Poznanski and Mokros 1996) total score compared with placebo from baseline to week 6 (Delbello et al. 2017). Key secondary endpoints included a change in Clinical Global Impressions-Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) (Guy 1976) from baseline to week 6 and rates of protocol-defined treatment-emergent hypomania or mania defined a priori as (1) a YMRS score ≥16 at any two consecutive postbaseline visits or at the final visit or (2) an adverse event of mania or hypomania. Additional outcome assessments included the YMRS, the Pediatric Anxiety Rating Scale

Birmaher and Axelson 2009). Further, up to 60% of adult patients with bipolar disorder experienced onset of mood symptoms before 21 years of age (Chengappa et al. 2003; Baldessarini et al. 2010).

Symptom profiles associated with mood disorder are complex and heterogeneous. In both unipolar and bipolar depression, manic symptoms often occur during episodes of depression (Zimmermann et al. 2009; Azorin et al. 2012; Swann et al. 2013; McIntyre et al. 2014; Suppes et al. 2016). In the systematic treatment enhancement program for bipolar disorder study, only one-third of the subjects were reported to have no manic symptoms during their depressive episode (Goldberg et al. 2009).

Bipolar I depression may be associated with mixed features, defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5; American Psychiatric Association 2013), as meeting full diagnostic criteria for a recent bipolar depressive episode and also experiencing at least three symptoms of mania or hypomania during the majority of the depressive episode. Compared with other subtypes of bipolar disorder, mixed features are frequently associated with worse symptoms, more frequent recurrence of acute episodes, poorer functioning and quality of life, increased risk of psychosis and suicidality, and greater challenges in finding effective treatments (Algorta et al. 2011; Frazier et al. 2017). However, in pediatric populations, mania symptoms may not meet clear diagnostic criteria due to lack of sufficient symptoms or a sufficient time frame. Nevertheless, the presence of mania symptoms during depression, however subsyndromal, can result in significant impairment in functioning and may complicate treatment selection due to concerns for treatment-emergent activation. Consequently, a systematic approach to an accurate diagnosis is critical to select effective and well-tolerated treatments, without unintended antidepressant-related activation or worsening of manic symptoms.

There has been limited research on the pharmacological management of bipolar depression with associated manic symptoms in youth or adults (Cuomo et al. 2017; ref for youth). Although there are several randomized controlled trials that support treatment for acute manic and mixed episodes in pediatric bipolar disorder (Findling 2016), there are no studies that have investigated the efficacy and safety of treating bipolar I depression with subsyndromal mania in this population. Therefore, there is a pressing need for effective evidence-based treatments for complex mood presentations in youth with bipolar depression.

Lurasidone is a second-generation antipsychotic agent that is approved for the treatment of bipolar depression in adults as monotherapy and as adjunctive therapy with lithium or valproate (Loebel et al. 2014a, b) and in children and adolescents as monotherapy (Delbello et al. 2017) in the United States and elsewhere. Lurasidone has also demonstrated efficacy for the treatment of adults with unipolar depression presenting with subsyndromal hypomanic symptoms (McIntyre et al. 2015; Suppes et al. 2016). In the systematic treatment enhancement program for bipolar disorder study, only one-third of the subjects were reported to have no manic symptoms during their depressive episode (Goldberg et al. 2009).

Lurasidone has also demonstrated efficacy for the treatment of acute depressive episodes (Suppes et al. 2016). In the systematic treatment enhancement program for bipolar disorder study, only one-third of the subjects were reported to have no manic symptoms during their depressive episode (Goldberg et al. 2009).

Consequently, a systematic approach to an accurate diagnosis is critical to select effective and well-tolerated treatments, without unintended antidepressant-related activation or worsening of manic symptoms.

Definition of subsyndromal hypomania features

Based on a median split of the study sample, a YMRS (Young et al. 1978) score ≥5 was used to define the presence of mixed (i.e., subsyndromal hypomanic) features at study baseline. We also conducted a sensitivity analysis using an alternative definition of subsyndromal hypomanic features that required the presence of two or more YMRS symptoms, each with a severity score of ≥2 at study baseline (Goldberg et al. 2009; Zimmermann et al. 2009; Azorin et al. 2012; Swann et al. 2013; Tohen et al. 2014).

Assessments

The primary endpoint in the underlying study was the change in the CDRS-R (Poznanski and Mokros 1996) total score compared with placebo from baseline to week 6 (Delbello et al. 2017). Key secondary endpoints included a change in Clinical Global Impressions-Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) (Guy 1976) from baseline to week 6 and rates of protocol-defined treatment-emergent hypomania or mania defined a priori as (1) a YMRS score ≥16 at any two consecutive postbaseline visits or at the final visit or (2) an adverse event of mania or hypomania. Additional outcome assessments included the YMRS, the Pediatric Anxiety Rating Scale

591
(PARS, 2002), the Children’s Global Assessment Scale (CGAS) (Bird et al. 1987), and Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) (Endicott et al. 2006).

**Statistical methods**

The population for the current analysis included all randomized subjects who received at least one dose of study medication and had at least one postbaseline assessment for any efficacy variable. The current post hoc analysis tested whether the antidepressant efficacy of lurasidone (vs. placebo) was similar in patients with or without mixed (subsyndromal hypomanic) features at the study baseline. Sensitivity analysis was conducted using the analysis of covariance (ANCOVA) model, which included terms for baseline score, age, strata, treatment, visit, and treatment by visit and interaction terms for mixed features, treatment, and visit.

**Results**

**Baseline characteristics**

Figure 1 shows the subject disposition of the study. At study baseline, mixed (subsyndromal hypomanic) features were present in 186 (54.2%) patients (YMRS score ≥ 5 based on median split). The subgroup with subsyndromal hypomanic features (vs. subgroup without subsyndromal hypomanic features) was more likely to be male (58.1% vs. 42.7%), have a history of attention-deficit/hyperactivity disorder (ADHD) (30.6% vs. 15.9%), and have higher baseline YMRS scores (7.9 ± 0.2 vs. 2.2 ± 0.1) (Table 1). Other clinical and demographic features were comparable between patient subgroups with or without subsyndromal hypomanic features (as assessed by the YMRS score), including baseline depressive symptom severity, age at onset of bipolar disorder, and past number of hospitalizations for bipolar disorder. At study baseline, the number of subjects using stimulants (for ADHD) was 13/30 (43.3%) for the lurasidone group and 8/12 (66.7%) for the placebo group.

**Table 1. Baseline Characteristics**

|                      | With subsyndromal hypomanic features (YMRS ≥ 5) | Without subsyndromal hypomanic features (YMRS < 5) |
|----------------------|-----------------------------------------------|---------------------------------------------------|
|                      | Lurasidone 20–80 mg/day Placebo | Placebo n=89 | Lurasidone 20–80 mg/day Placebo | Placebo n=81 |
| Age, mean±SD, years  | 13.6 ± 2.2 | 14.1 ± 2.2 | 14.8 ± 2.0 | 14.5 ± 1.9 |
| Age at onset of bipolar disorder, mean±SD, years | 11.8 ± 2.7 | 11.6 ± 2.8 | 13.4 ± 2.6 | 12.8 ± 2.4 |
| Male, n (%)          | 54 (55.7%) | 54 (60.7%) | 34 (44.7%) | 33 (40.7%) |
| Race, n (%)          | 69 (71.1%) | 58 (65.2%) | 65 (85.5%) | 67 (82.7%) |
| White                | 14 (14.4%) | 18 (20.2%) | 1 (1.3%) | 0 |
| Black/African American | 2 (2.1%) | 3 (3.4%) | 5 (6.6%) | 1 (1.2%) |
| Asian                | 12 (12.4%) | 10 (11.2%) | 5 (6.6%) | 13 (16.1%) |
| Other                | 27 (27.8%) | 25 (28.1%) | 17 (22.4%) | 24 (29.6%) |
| ADHD diagnosis       | 30 (30.9%) | 27 (30.3%) | 13 (17.1%) | 12 (14.8%) |
| ADHD treated with stimulants | 13/30 | 13/27 | 5/13 | 8/12 |
| CDRS-R total score, mean±SD | 59.3 ± 7.9 | 58.1 ± 8.6 | 59.2 ± 8.7 | 59.1 ± 7.9 |
| CGI-BP-S depression score, mean±SD | 4.7 ± 0.7 | 4.5 ± 0.6 | 4.5 ± 0.6 | 4.4 ± 0.5 |
| YMRS total score, mean±SD | 8.2 ± 2.8 | 7.6 ± 2.1 | 2.1 ± 1.5 | 2.3 ± 1.5 |

ADHD, attention-deficit/hyperactivity disorder; CDRS-R, Children’s Depression Rating Scale-Revised; CGI-BP-S, Clinical Global Impressions-Bipolar Severity; YMRS, Young Mania Rating Scale; SD, standard deviation.
the treatment of ADHD) was 26 (14.0%) in the group with mixed (subsyndromal hypomanic) features (YMRS >5) and 13 (8.3%) in the group without mixed (subsyndromal hypomanic) features.

Efficacy

Treatment with lurasidone (vs placebo) was associated with significantly greater reduction in CDRS-R scores at week 6 in the group with subsyndromal hypomanic features (LSM –21.48 vs –15.94; p=0.004; effect size, 0.43, MMRM) and in the group without subsyndromal hypomanic features (–20.55 vs –14.86; p=0.006; effect size, 0.44, MMRM) (interaction between treatment and mixed features, effect at week 6: p=0.958, F=0.0025, df=1, 331, MMRM; p=0.768, F=0.09, df=1, 322, ANCOVA) (Fig. 2; Table 2). There was no significant interaction between lurasidone treatment and the presence (vs. absence) of subsyndromal hypomanic features by visit for change in CDRS-R scores (p=0.593, F=0.74, df=5, 331, MMRM). Lurasidone was associated with significantly greater reductions in CDRS-R scores from baseline compared with placebo, starting at week 2, in patients with subsyndromal hypomanic features (Fig. 3). In patients without subsyndromal hypomanic features, lurasidone was superior to placebo in change from baseline in CDRS-R scores from week 4 onward (Fig. 3).

Change in CDRS-R score was significantly associated with change in the YMRS score in the subgroup with subsyndromal hypomanic features (r=0.49, p<0.001), but not in the subgroup without subsyndromal hypomanic features (r=0.10, p=0.222) (treatment interaction with change in the YMRS score p=0.031, F=4.69, df=1, ANCOVA).

**FIG. 2.** Change in Children’s Depression Rating Scale-Revised in patients with and without mixed (subsyndromal hypomanic) features (based on the YMRS score). YMRS, Young Mania Rating Scale.

### Table 2. Efficacy Outcome by the Presence or Absence of Mixed Features at Study Baseline

|                      | With subsyndromal hypomanic features (YMRS ≥5) | Without subsyndromal hypomanic features (YMRS <5) |
|----------------------|-----------------------------------------------|-------------------------------------------------|
|                      | Lurasidone n=97 Placebo n=89                  | Lurasidone n=76 Placebo n=81                     |
|                      | LS mean SD LS mean SD                         | LS mean SD LS mean SD                           |
| CDRS-R total         | –21.48** 12.96 −15.94 12.96                   | –20.55*** 12.83 −14.86 12.83                    |
| CGI-BP-S depression score | −1.61**** 1.04 −1.08 1.04                     | −1.33* 1.03 −1.01 1.03                          |
| YMRS total           | −2.98**** 3.47 −1.23 3.47                     | −0.98 3.42 −1.26 3.42                           |
| PARS                 | −2.97 4.98 −1.44 4.98                         | −3.85* 4.93 −3.06 4.93                          |
| CGAS                 | 14.08*** 1.28 9.82 1.33                       | 14.02** 1.34 8.87 1.33                           |
| Pediatric Q-LES-Q    | 11.42 12.72 8.50 12.72                        | 12.30* 12.50 7.39 12.50                          |

**Secondary analysis**

|                      | With subsyndromal hypomanic features Baseline ≥2 on 2 or more YMRS items | Without subsyndromal hypomanic features Baseline <2 YMRS items |
|----------------------|-------------------------------------------------------------------------|-------------------------------------------------|
|                      | Lurasidone n=89 Placebo n=78                                          | Lurasidone n=84 Placebo n=92                     |
|                      | LS mean SD LS mean SD                                                  | LS mean SD LS mean SD                           |
| CDRS-R total         | −21.46* 12.96 −16.59 12.96                                             | −20.60** 12.86 −14.36 12.86                     |
| CGI-BP-S depression score | −1.62*** 1.04 −1.12 1.04                                               | −1.35* 1.03 −0.99 1.03                          |

*p<0.05 (lurasidone vs. placebo).

**p<0.01 (lurasidone vs. placebo).

***p<0.001 (lurasidone vs. placebo).

CDRS-R, Children’s Depression Rating Scale-Revised; CGI-BP-S, Clinical Global Impressions-Bipolar Severity; YMRS, Young Mania Rating Scale; PARS, Pediatric Anxiety Rating Scale; CGAS, Children’s Global Assessment Scale; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; Pediatric Q-LES-Q is the percent of the maximum possible score; SD, model estimate of pooled standard deviation; LS, least squares.
Among patients with subsyndromal hypomanic features, mediational analysis showed that 50.1% of the total lurasidone treatment effect size for improvement in the CDRS-R score at week 6 was due to the change in the YMRS score (lurasidone $-2.98 \pm 3.47$ vs. placebo $-1.23 \pm 3.47$) ($p < 0.001$, $F = 12.89$, df = 1, 332). Among patients without subsyndromal hypomanic features, change in the YMRS score at week 6 was not significant comparing lurasidone versus placebo treatment (Table 2).

Lurasidone was associated with a greater effect size for reductions in CGI-BP-S scores at week 6 in the subgroup with subsyndromal hypomanic features ($-1.61$ vs. $-1.08$; $p < 0.001$; effect size 0.51) compared with the subgroup without subsyndromal hypomanic features ($-1.33$ vs. $-1.01$; $p = 0.05$; effect size 0.31) (interaction between treatment and mixed features, effect at week 6: $p = 0.342$, $F = 0.903$, df = 1, 330, MMRM; $p = 0.281$, $F = 1.17$, df = 1, 330, ANCOVA) (Fig. 4; Table 2). There was no significant interaction between treatment (vs. placebo) and the presence (vs. absence) of subsyndromal hypomanic features by visit for change in CGI-BP-S scores ($p = 0.223$, $F = 1.40$, df = 5, 330, MMRM). No statistical interaction was observed between lurasidone treatment (vs. placebo) and the presence (vs. absence) of mixed (subsyndromal hypomanic) features for PARS (interaction between treatment and mixed features, effect at week 6: $p = 0.498$, $F = 0.462$, df = 1, 321), CGAS (interaction between treatment and mixed features, effect at week 6: $p = 0.715$, $F = 0.137$, df = 1, 321), and PQ-LES-Q ($p = 0.473$, $F = 0.518$, df = 1, 320) (Table 2).

**Safety and Tolerability**

The rate of discontinuation was low in both the lurasidone (<9%) and placebo (<13%) groups with or without the presence of mixed (subsyndromal hypomanic) features (Fig. 1). Rates of protocol-defined treatment-emergent hypomania or mania were similar for lurasidone and placebo groups in patients with mixed (subsyndromal hypomanic) features (lurasidone 8.2% vs. placebo 9.6%).

**Sensitivity analysis using alternative criteria for mixed (subsyndromal hypomanic) features**

Consistent findings were observed using criteria for subsyndromal hypomanic features defined by a baseline severity score of ≥2 or more YMRS symptoms. There was no significant interaction between treatment (vs. placebo) and the presence (vs. absence) of subsyndromal hypomanic features by visit for change in CDRS-R (treatment-by-mixed features-by visit interaction effect $p = 0.704$, $F = 0.59$, df = 5, 330, MMRM) and CGI-BP-S (treatment-by-mixed features-by visit interaction effect $p = 0.406$, $F = 1.02$, df = 5, 330, MMRM) scores. We found that lurasidone was associated with significantly greater reductions of CDRS-R and CGI-BP-S scores from baseline to week 6 in patients with subsyndromal hypomanic features and without subsyndromal hypomanic features ($\leq 1$ YMRS symptom with a severity score of ≥2 at study baseline) (Fig. 5; Table 2).
9.0%) or without mixed (subsyndromal hypomanic) features (lurasidone 1.3% vs. placebo 3.7%) (Fig. 6). Table 3 shows that the frequency and proportion of treatment-emergent adverse events (TEAEs) between lurasidone and placebo were comparable in patients with and without mixed (subsyndromal hypomanic) features. Treatment-emergent suicidal ideation occurred in one patient in the placebo group without subsyndromal hypomanic features and in none of the lurasidone-treated patients (with or without subsyndromal hypomanic features).

Discussion

In this post hoc analysis of a placebo-controlled study in children and adolescents with bipolar depression, a majority of patients (54%) met the severity criterion for mixed (i.e., subsyndromal hypomanic) features (YMRS score ≥5) at study baseline. These findings are consistent with previously reported prevalence rates of mixed features in adults with bipolar depression, which ranged from 11% to 54% depending on the study setting and criteria used (Azorin et al. 2012; Swann et al. 2013; Vieta and Valenti 2013; McIntyre et al. 2014). In this study, lurasidone treatment (vs. placebo) was effective in patients with bipolar depression presenting with or without mixed (subsyndromal hypomanic) features at the study baseline, as assessed by reduction of depressive and overall clinical symptom severity (CDRS-R and CGI-BP-S). To our knowledge, this is the first analysis of acute treatment for youth with bipolar depression with mixed (subsyndromal hypomanic) features. We found consistent results for the antidepressant efficacy of lurasidone (vs. placebo) in young patients when subsyndromal hypomanic features were defined by either the YMRS score (YMRS total score ≥5 vs. YMRS total score <5) or the presence of two or more YMRS items, each with a severity item score of ≥2. These findings suggest that therapeutic responses to lurasidone treatment were independent of the presence, number, and severity of mixed (subsyndromal hypomanic) features at study baseline, as indicated by the nonsignificant interaction effect between treatment (vs. placebo) and the presence (vs. absence) of mixed (subsyndromal hypomanic) features, utilizing two different definitions for subsyndromal hypomanic features. Results of the current post hoc analysis are consistent with findings reported in a previously published post hoc analysis of adult patients with bipolar I depression with mixed (subsyndromal hypomanic) features treated with lurasidone or placebo (McIntyre et al. 2015).

Lurasidone also showed a greater level of improvement in measures of anxiety, quality of life, and functioning, compared with placebo, in groups both with and without mixed (subsyndromal hypomanic) features. We note that lurasidone (vs. placebo) treatment was associated with improvement in both depressive and manic symptoms in this post hoc analysis. In the group with mixed (subsyndromal hypomanic) features, we found (based on mediational analysis) that the reduction of manic symptom severity from baseline...
to week 6 accounted for half of the lurasidone treatment effect size for improvement in depressive symptoms.

In the current analysis, TEAE profiles of lurasidone and placebo were comparable in groups with or without mixed (subsyndromal hypomanic) features. Rates of treatment-emergent hypomania were comparable with placebo in patients with or without mixed (subsyndromal hypomanic) features at baseline. Lurasidone was found to be generally safe and well tolerated in the parent, 6-week, double-blind placebo-controlled trial (Delbello et al. 2017) and in the subsequent 2-year, open-label follow-up study (Delbello et al. 2019).

Existing studies that examined the impact of mixed (subsyndromal hypomanic) features on treatment response in patients with bipolar depression are relatively scarce. Frye et al. (2009) suggested that even mildly elevated baseline YMRS scores in bipolar depression predispose patients to higher risks of nonresponse and treatment-emergent mania during combined antidepressant/mood stabilizer therapy. Two short-term trials of another atypical antipsychotic, olanzapine, as monotherapy or in combination with the antidepressant, fluoxetine, in the treatment of bipolar depression, reported an inverse relationship between the number and severity of mixed features and proportion of responders among enrolled patients (Tohen et al. 2014). In contrast, both the present study in children and adolescents and the previous analysis in adults (McIntyre et al. 2015) with bipolar depression associated with mixed (subthreshold hypomanic) features found that the presence and severity of subsyndromal hypomanic features did not have a significant impact on lurasidone treatment response in patients with bipolar depression.

We note a few limitations of the current study. First, this is a post hoc analysis, not based on a specifically designed prospective trial to test the efficacy of lurasidone in young bipolar patients with mixed features. Second, the criteria for mixed (subsyndromal hypomanic) features used here were based on YMRS severity score. Several YMRS items (irritability, disruptive/aggressive, and distractability) are not included in the DSM-5 criteria for mixed features, but are common in pediatric bipolar presentations (Van Meter et al. 2016), especially in the context of co-occurring attention deficit with hyperactivity. Further, the DSM-5 specifier criteria mandate that mixed features be present for the majority of the depressive episode, whereas the present analysis relied on an assessment conducted at baseline to determine the presence of mixed (subsyndromal hypomanic) features. Additional studies, preferably involving prospectively designed, longer-term longitudinal trials, to further verify the impact of mixed (subsyndromal hypomanic) features on treatment of bipolar depression in different patient populations are warranted.

Conclusions

This post hoc analysis of a randomized placebo-controlled trial shows that lurasidone was efficacious in children and adolescents with bipolar depression associated with mixed (subthreshold hypomanic) features. Our findings suggest that the presence of these mixed features did not influence the antidepressant efficacy of lurasidone, with significant improvement in depressive symptoms, anxiety, and quality of life found in the groups with or without subsyndromal hypomanic features. No differences in safety profile, including risk for treatment-emergent mania, were observed in patients with or without subsyndromal hypomanic features in this study. Additional prospective studies are needed to confirm these findings.

Clinical Significance

These findings provide empirical data to support the use of lurasidone in children and adolescents with bipolar depression associated with mixed (subthreshold hypomanic) features. The presence of mixed features did not influence the antidepressant efficacy of lurasidone. No increased risk of treatment-emergent mania was found in patients with or without subsyndromal hypomanic features in this study.

Role of the Sponsor

This study was sponsored by Sunovion Pharmaceuticals, Inc. The sponsor was involved in the design and collection of data. This publication is the work of authors. Dr. C.S. served as a statistical expert for this post hoc analysis.

Author’s Contributions

All authors contributed to the analysis and interpretation of data, drafted the manuscript, and approved the submitted version of the manuscript.

Table 3. Treatment-Emergent Adverse Events with Incidence ≥5% (Safety Population)

|                          | With subsyndromal hypomanic features (YMRS ≥5) | Without subsyndromal hypomanic features |
|--------------------------|-----------------------------------------------|-----------------------------------------|
|                          | Lurasidone 20–80 mg (n = 98) Placebo (n = 91) | Lurasidone 20–80 mg (n = 77) Placebo (n = 81) |
| Headache                 | 16 (16.3%)                                    | 9 (11.7%)                               |
| Nausea                   | 15 (15.3%)                                    | 13 (16.9%)                              |
| Vomiting                 | 8 (8.2%)                                      | 3 (3.9%)                                |
| Somnolence               | 10 (10.2%)                                    | 6 (7.8%)                                |
| Weight increased         | 8 (8.2%)                                      | 4 (5.2%)                                |
| Decreased appetite       | 5 (5.1%)                                      | 2 (2.6%)                                |
| Dizziness                | 5 (5.1%)                                      | 4 (4.4%)                                |
| Fatigue                  | 5 (5.1%)                                      | 1 (1.3%)                                |
| Insomnia                 | 5 (5.1%)                                      | 4 (5.2%)                                |
| Influenza                | 0 (0%)                                        | 4 (5.2%)                                |
| Nasopharyngitis          | 2 (2.0%)                                      | 5 (6.5%)                                |

YMRS, Young Mania Rating Scale.
Disclosures

Dr. M.K.S. receives research support from the National Institute of Mental Health, National Institute on Aging, Johnson & Johnson, Allergan, Brain & Behavior Research Foundation, Patient-Centered Outcomes Research Institute, and Stanford’s Maternal Child Health Research Institute and Department of Psychiatry, and receives royalties from the American Psychiatric Association Publishing. She is on the advisory board for Sunovion and is a consultant for Google X and Limbix. Dr. C.S. reports having received consulting fees from Sunovion, the Chinese University of Hong Kong, and the Centre for Addiction and Mental Health, Toronto, in the past 3 years. Drs. A.L., A.P., and M.T. are employees of Sunovion Pharmaceuticals, Inc. Sunovion Pharmaceuticals, Inc., is part of a clinical trial data sharing consortium that facilitates access for qualified researchers to selected anonymized clinical trial data. For up-to-date information on data availability, please visit https://clinicalstudycoderequest.com/Study-Sponsors.aspx and click on Sunovion.

References

Algota GP, Youngstrom EA, Frazier TW, Freeman AJ, Youngstrom JK, Findling RL: Suicidality in pediatric bipolar disorder: Predictor or outcome of family processes and mixed mood presentation? Bipolar Disord 13:76–86, 2011.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.

Axelson D, Birmaher B, Strober M, Gill MK, Valeri S, Chiappetta L, Ryan N, Leonard H, Hunt J, Iyengar S, Bridge J, Keller M: Prenomnology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 63:1139–1148, 2006.

Azorin JM, Kaladjian A, Adida M, Fakra E, Belzeaux R, Hantouche E, Lancrenon S: Self-assessment and characteristics of mixed depression in the French national EPIDEP study. J Affect Disord 43:109–117, 2012.

Baldessarini RJ, Bolzani L, Cruz N, Jones PB, Lai M, Lepri B, Perez J, Salvatore P, Tohen M, Tondo L, Vieta E: Onset-age of bipolar disorders at six international sites. J Affect Disord 121:143–146, 2010.

Bird HR, Canino G, Rubio-Stipec M, Ribera JC: Further measures of the psychometric properties of the Children’s Global Assessment Scale. Arch Gen Psychiatry 44:821–824, 1987.

Birmaher B: Bipolar disorder in children and adolescents. Child Adolesc Ment Health 18 [Epub ahead of print]; DOI: 10.1111/camh.12021, 2013.

Birmaher B, Axelson D: Four-year longitudinal course of children and adolescents with bipolar spectrum disorder: The Course and Outcome of Bipolar Youth (COBY) Study. Am J Psychiatry 166:795–804, 2009.

Chang K: Adult bipolar disorder is continuous with pediatric bipolar disorder. Can Psychiatry 52:418–425, 2007.

Chengappa KN, Kupfer DJ, Frank E, Houck PR, Grochocinski VJ, Cluss PA, Staff DA: Relationship of birth cohort and early age at onset of illness in a bipolar disorder case registry. Am J Psychiatry 160:1636–1642, 2003.

Cuomo A, Nikolova VL, Yalin N, Arnone D, Fagiolini A, Young AH: Pharmacological treatment of mixed states. CNS Spectr 22:186–195, 2017.

Delbello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A: Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: A double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 56:1015–1025, 2017.

Delbello MP, Goldman R, Tocco M, Pikalov A, Deng L, Loebel A: Efficacy and safety of lurasidone in children and adolescents with bipolar depression: Results from a 2-year open-label extension study. Presented at American Psychiatric Association May 18–22, 2019, San Francisco, CA.

Dilsaver SC, Benazzi F, Akiskal HS: Mixed states: The most common outpatient presentation of bipolar depressed adolescents? Psycho-pathology 38:268–272, 2005.

Endicott J, Nee J, Yang R, Wohlberg C: Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): Reliability and validity. J Am Acad Child Adolesc Psychiatry 45:401–407, 2006.

Findling RL: Evidence-based pharmacologic treatment of pediatric bipolar disorder. J Clin Psychiatry 77 Suppl E1-e2, 2016.

Findling RL, Gracious BL, McNamara NK, Youngstrom EA, Demeter CA, Branicky LA, Calabrese JR: Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord 3:202–210, 2001.

Frazier EA, Swenson LP, Mullare T, Dickstein DP, Hunt JI: Depression with mixed features in adolescent psychiatric patients. Child Psychiatry Hum Dev 48:393–399, 2017.

Frye MA, Helleman G, McElroy SL, Altsuler LL, Black DO, Keck PE Jr., Nolen WA, Kupka R, Leverich GS, Grunze H, Mintz J, Post RM, Suppes T: Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 166:164–172, 2009.

Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marambell LG, Calabrese JR, Nierenberg AA, Sachs GS: Manic symptoms during depressive episodes in 1380 patients with bipolar disorder: Findings from the STEP-BD. Am J Psychiatry 166:173–181, 2009.

Goldstein TR, Birmaher B, Axelson D, Ryan ND, Strober MA, Gill MK, Valeri S, Chiappetta L, Leonard H, Hunt J, Bridge JA, Brent DA, Keller M: History of suicide attempts in pediatric bipolar disorder: Factors associated with increased risk. Bipolar Disord 7:525–535, 2005.

Goldstein TR, Birmaher B, Axelson D, Goldstein BI, Gill MK, Esposito-Smythers C; Ryan ND, Strober MA, Hunt J, Keller M: Psychosocial functioning among bipolar youth. J Affect Disord 114:174–183, 2009.

Guy W: ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76–338. Rockville (Maryland), National Institute of Mental Health, 1976.

Keenan-Miller D, Miklowitz DJ: Interpersonal functioning in pediatric bipolar disorder. Clin Psychol Sci Pract 18:342–356, 2011.

Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G: Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double blind, placebo-controlled study. Am J Psychiatry 171:160–168, 2014a.

Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR: Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry 171:169–177, 2014b.

McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A: Lurasidone in the treatment of bipolar depression with mixed (sub-syndromal hypomanic) features: Post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 76:398–405, 2015.

McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsouwaidan MT, Gallaugher LA, Mansur RB, Muzina DJ, Carvalho A, Kennedy SH: The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. J Affect Disord 172C:259–264, 2014.
Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543–552, 2007.
Poznanski EO, Mokros HB: Children’s Depression Rating Scale- Revised: Manual. Los Angeles (California), Western Psychological Services, 1996.
Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, Pikalov A, Loebel A: Lurasidone for the treatment of major depressive disorder with mixed features: A randomized, double-blind, placebo-controlled study. Am J Psychiatry 173:400–407, 2016.
Swann AC, Lafer B, Perugi G, Frye MA, Bauer M, Bahk WM, Scott J, Ha K, Suppes T: Bipolar mixed states: An International Society for Bipolar Disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry 170:31–42, 2013.
The Pediatric Anxiety Rating Scale (PARS): Development and psychometric properties. J Am Acad Child Adolesc Psychiatry 41: 1061–1069, 2002.
Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H: Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord 164:57–62, 2014.
Van Meter AR, Burke C, Kowatch RA, Findling RL, Youngstrom EA: Ten-year updated meta-analysis of the clinical characteristics of pediatric mania and hypomania. Bipolar Disord 18:19–32, 2016.
Van Meter AR, Moreira AL, Youngstrom EA: Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry 72:1250–1256, 2011.
Vieta E, Valenti M: Mixed states in DSM-5: Implications for clinical care, education, and research. J Affect Disorder 148:28–26, 2013.
Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133: 429–435, 1978.
Youngstrom E, Youngstrom JK, Starr M: Bipolar diagnoses in community mental health: Achenbach Child Behavior Checklist profiles and patterns of comorbidity. Biol Psychiatry 58:569–575, 2005.
Zimmermann P, Bruckl T, Nocon A, Pfister H, Lieb R, Wittchen HU, Holsboer F, Angst J: Heterogeneity of DSM-IV major depressive disorder as a consequence of subsyndromal bipolarity. Arch Gen Psychiatry 66:1341–1352, 2009.

Address correspondence to:
Manpreet K. Singh, MD, MS
Psychiatry and Behavioral Sciences
Stanford University
Stanford, CA
USA

E-mail: mksingh@stanford.edu